Cyprotex PLC Director Dealing 14 November 2014 (1158X)

TIDMCRX

RNS Number : 1158X

Cyprotex PLC

14 November 2014

Press Release

Cyprotex PLC

("Cyprotex" or "the Company")

Director dealing

The Company received notification that Dr. Anthony Baxter, Chief Executive Officer of the Company, acquired 11,000 ordinary shares in the Company on 14 November 2014 at a price of 40 pence per share. His wife, Mrs. Helen Baxter has today also acquired 5,200 ordinary shares in the Company at a price of 40p pence per share. As a result of this purchase, Dr. Baxter (together with connected parties, including his wife) has a beneficial interest in 132,374 ordinary shares in the Company representing approximately 0.59 per cent. of the Company's total voting rights.

 
 
 
 
 
   Cyprotex PLC 
                                           Tel : [phone] 
                                           505 100 
 Dr Anthony Baxter, Chief Executive 
  Officer 
 John Dootson, Chief Financial Officer 
 Mark Warburton, Chief Operating 
  Officer and Legal Counsel 
 [e-mail]                         www.cyprotex.com 
 
 N + 1 Singer (NOMAD and broker to       Tel : +44 (0)20 
  Cyprotex)                               7496 3000 
 Shaun Dobson 
 [e-mail] 
 Jen Boorer 
 [e-mail]                 www.nplus1singer.com 
 
 

About Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites in Macclesfield, near Manchester in the UK, Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1,000 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe(R) PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSEZLFFZFFXFBB